Resultados finales
SkinBioTherapeutics plc
("SkinBioTherapeutics" o "la Compañía")
Resultados del año completo
30 de noviembre de 2023 - SkinBioTherapeutics plc (AIM: SBTX, or the "Company"), the life science business focused on skin health, announces the fully consolidated audited results for the 12 months to 30 June 2023.
Aspectos operacionales destacados
· The Skinbiotix? partnership with Croda plc product development phase continues well:
o Successful scale-up of manufacturing
o Post financial year end, contract to extend for a further 12 months to enable exploration of potential additional claims
· ¿AxisBiotix-Ps?
o Solid sales growth in the UK; expansion of sales distribution into Europe during the year in Spain and post period end in Italy and France
o Monthly retention rates of subscribers remain at 80%+
o Publicar fin de año
§ Start of recruitment of participants for the consumer study with acne food supplement; results expected in Q1 2024
§ Launch on Amazon UK
· Oral research and inflammation programmes continue at the University of Manchester
· Management continuing to investigate potential accretive inorganic opportunities that provide synergies and accelerated routes to market; update on progress expected in the near term
Aspectos financieros más destacados
· Revenues up to £132k (2022: £75k) boosted by solid increase in UK revenues.
· Operating at loss £2,999k (2022: loss £2,982k) with increase in sales balancing the increase in headcount costs
· Cash and cash equivalents as at 30 June was £1.3m (2022: £1.8m), following successful Placing and Open Offer in January 2023
o Post year end, the Company raised an additional £3.3m (gross) in a Placing and Retail Offer in November 2023
· Cambio de auditores de la Compañía debido a reorganización societaria de auditores
Stuart Ashman, director ejecutivo de SkinBioTherapeutics, dijo:
"In 2023, we introduced AxisBiotix-PS? into new European territories, beginning with Spain then moving onto France and Italy. Launching a disruptive product into any market always takes time to establish, and given our limited resources, we are pleased with the loyalty and the very positive testimonials we are receiving.
"We continue to enjoy a positive relationship with the Croda/Sederma teams and they have provided very supportive commentary on their views of the SkinBiotix? technology. We see their wish to extend the collaboration for a further 12 months as very positive; it may slightly delay near-term revenue generation, but the potential enhanced commercial opportunities could be quite considerable. All costs for the extension and the resulting clinical grade study are met directly by Croda."
"Next year should also see the early results from other studies, including the consumer study around an acne product, as well as results from our oral and inflammation programmes with Manchester University. The acne programme is especially exciting. We saw initial positive responses to AxisBiotix-Ps in participants of the psoriasis study who had other skin conditions, and this has resulted in this new development programme which could have a significant impact on a much wider population.
"Talks with potential strategic partners continue around our other pillars. We are also pushing ahead with our inorganic acquisition programme, looking for opportunities that are synergistic and complement our current programmes. We have strict criteria for these opportunities; we will not overpay and they must be accretive from day one."
-Fin-
La información comunicada en este anuncio contiene información privilegiada a los efectos del artículo 7 del Reglamento de abuso de mercado (UE) nº 596/2014.
Para más información, por favor contacte:
SkinBioTherapeutics plc Stuart j. Ashman, director ejecutivo Manprit Randhawa, director financiero
| Tel: + 44 (0) 191 495 7325 |
Cavendish Capital Markets Limitado Giles Balleny, Dan Hodkinson (Finanzas corporativas) Charlie Combe (corretaje) Dale Bellis, Tamar Cranford-Smith (Ventas)
| Tel: + 44 (0) 20 7397 8900 |
Instinctif Partners (prensa financiera) Melanie Toyne-Sewell / Jack Kincade | Tel: + 44 (0) 20 7457 2020 PielBioTGME@dhr-rgv.com |
Notas a los editores
Acerca de SkinBioTherapeutics plc
SkinBioTherapeutics es una empresa de ciencias de la vida centrada en la salud de la piel. La tecnología de plataforma patentada de la empresa, SkinBiotix®, se basa en los descubrimientos realizados por la profesora Catherine O'Neill y el profesor Andrew McBain.
La empresa se dirige a varios sectores del cuidado de la piel, los más avanzados de los cuales son el cuidado cosmético de la piel y los complementos alimenticios para modular el sistema inmunológico aprovechando el eje intestino-piel. En cada área, SkinBioTherapeutics planea ejemplificar su tecnología a través de estudios en humanos. El primer producto de la compañía, AxisBiotix-Ps?, un complemento alimenticio para abordar los síntomas de la psoriasis leve a moderada.
La empresa cotizó en AIM en abril de 2017 y tiene su sede en Newcastle, Reino Unido. Para más información visite: www.skinbiotherapeutics.com y www.axisbiotix.com.
Precaución con respecto a las declaraciones prospectivas
Ciertas declaraciones en este anuncio son, o pueden considerarse, declaraciones prospectivas. Las declaraciones prospectivas se identifican por el uso de términos y frases como "creer", "podría", "debería", "prever", "estimar", "pretender", " 'podrá', 'planificar', 'potencialmente', 'esperar', 'voluntad' o el negativo de aquéllos, variaciones o expresiones comparables, incluidas las referencias a supuestos. Estas declaraciones prospectivas no se basan en hechos históricos sino más bien en las expectativas y suposiciones actuales de los Directores con respecto al crecimiento futuro, los resultados de las operaciones, el desempeño, el capital futuro y otros gastos del Grupo (incluido el monto, la naturaleza y las fuentes de financiamiento de los mismos). , ventajas competitivas, perspectivas y oportunidades de negocio. Dichas declaraciones prospectivas reflejan las creencias y suposiciones actuales de los Directores y se basan en información actualmente disponible para los Directores.
Declaración del presidente y director ejecutivo
General
The year for SkinBioTherapeutics has been dominated by growing the sales of AxisBiotix-Ps? in the UK and expanding sales and distribution channels into Europe, starting with Spain. Beyond the commercial operations, the Company has continued its research programmes alongside the University of Manchester, and engaging with partners and potential strategic partners across the other business pillars, including SkinBiotix, and MediBiotix. Management is also pushing its inorganic acquisition strategy forward with the aim to generate further shareholder value in the near to medium term.
Revisión financiera
Reported sales for the full year were £132k (2022: £75k), in line with management expectations, as UK sales continued to increase slowly but steadily, and the introduction of new European regions.
Cost of sales were £46k (2022: £29k) and gross profits were £85k (2022: £45k). As shipping volumes have increased, the Company is seeing a gradual improvement in the operating margin.
Total administrative expenses were £3,085k (2022: £3,027k), comprising research and development expenditure of £931k (2022: £861k), which includes the ongoing cost of the inflammation programme, and in oral health and wellbeing research programme. Selling and distribution costs were £81k (FY22 £44k) due to an increase in volumes of product being sold. Ongoing operating expenses were £2,073k (2022: £2,122k).
The operating loss was £2,999k (2022: £2,982k).
The cash and cash equivalents balance as at 30 June 2023 was £1.3m (2022: £1.8m) reflecting tight control on costs and was boosted by the Placing and Open Offer which raised 2.6m of gross proceeds to fund future operations. Post year end, the Company raised an additional £3.3m (gross) in a Placing and Retail Offer in November 2023.
Actualización sobre los auditores de la Compañía
Jeffreys Henry LLP has indicated that it will resign as the Company's Auditor as the firm will provide audit services to clients from another company in the group, Gravita Audit Limited. This is following a business reorganisation at the auditors. As announced in the FY22 Annual Report, Gravita Audit Limited has been appointed as the Company's auditor for the financial year ending 30 June 2023.
Jeffreys Henry LLP ha confirmado a la Compañía que, de conformidad con la Sección 519 de la Ley de Sociedades de 2006, no hay circunstancias en relación con su renuncia que considere necesario comunicar a los miembros o acreedores de la Compañía.
Perspectivas y comercio actual
Revenues of AxisBiotix-Ps? have continued to increase following the year end, with an increase in the monthly run rate hitting £20k+, with revenues on course to double to c£250k for the year ending 30 June 2024.
Retention rates for subscribers continue to be at least 80% with retention rates being measured as the number of subscribers who are remaining as a subscriber at the end of each month, compared to the same cohort that were in existence at the start of the previous month.
The Group also successfully completed a fundraise in November 2023, raising gross proceeds of £3.3m which will allow it to continue its R&D programmes, continue marketing of AxisBiotix-PS in the UK and Europe, and fund operating expenditure.
Estrategia de adquisicion
The Group is in advanced discussions to acquire two private companies that either manufacture or sell a variety of branded topical products for common dermatological conditions to NHS hospitals, dispensing practices and national pharmacy chains. The proposed targets are profitable and the Group sees a number of synergies to improve this. However, there is no certainty of timing or execution as the Company would need to agree additional funding using debt and/or equity and any acquisition would be conditional on satisfactory diligence.
In addition, the Group has a pipeline of further acquisitions where active discussions are taking place. Any targets which the Group is interested in purchasing will be accretive from a revenue and earnings perspective, and thus reduce the operating cash burn, with the goal of the Group in the next 12-18 months to becoming a cash generating entity.
Revisión operativa
PielBiotix? Pilar (cuidado de la piel/cosméticos)
In November 2019, SkinBioTherapeutics signed a commercial and manufacturing agreement with Croda's Consumer Care division, Sederma, which is a specialist in bioactive ingredients for the cosmetic industry. Croda has a global portfolio of personal care customers which comprise many of the major international cosmetics and FMCG brands.
During this financial year, Sederma has been focused on developing quality formulations with their customers, which has seen scaling-up manufacture of SkinBiotix? from 600 litres to 2,000 litres which is expected to ultimately lead to the 20,000 litres vessel required to service the global market. 4 pilot batches have been manufactured which identified significant, unexpected technical benefits which Sederma believes may lead to a justifiable increase in price based on clinical evidence. To this end, the company extended its development agreement with Croda plc to allow a clinical trial to be carried out to evidence the additional activity. This study is fully funded by Sederma /Croda and is expected to be completed early 2024.
Post year end, in November, Sederma extended its contract with SkinBioTherapeutics for a further 12 months to conduct these studies which are due to run from late 2023 into early 2024.
¿AxisBiotix? Pilar (eje intestino/piel)
The AxisBiotix pillar has challenged management time in the year, as efforts to grow the UK market and expanding sales and distribution channels into Europe, as well as driving the Acne programme forward.
- ¿AxisBiotix? (Soriasis)
Management has continued to grow the sales of the AxisBiotix-Ps? food supplement designed to alleviate the symptoms associated with irritable skin conditions like psoriasis in the UK and Europe.
The primary focus has been growing the UK market, whilst keeping a strong control on costs, which has led to a reduction in marketing expenditure with the completion of the influencer programme. The response from customers continues to be extremely positive with the retention rates of AxisBioTix-Ps? in the UK staying at 80% or above, which is encouraging. The retention rate is measured as the number of subscribers who remain a subscriber at the end of each monthly period, compared to the same cohort that were in existence at the start of a month period. This is an important statistic for the product, along with the increasing number of positive testimonials from customers describing the impact that this product has had on their lives.
This year was marked by the expansion into Europe, initially in Spain in February 2023. Spain was management's first country target since the market for psoriasis is similar to the UK with incidence rates of psoriasis of between 1%-3% of the population. Post period end, the Company opened new markets in Italy and France. The Company also announced today that AxisBiotix-Ps? will be sold on Amazon's UK platform; the aim will be to expand this into other countries, starting with European countries where the product already has regulatory approval - Spain, Italy and France.
Work continues with Winclove, our formulation partner, to investigate other delivery vehicles for SkinBiotix, for example capsules, tablets etc which we hope to announce in 2024. These will bring with them economic benefits to the Group.
Discussions with potential multinational partners are on-going and are supported by our current activities. Partnering discussions can take time and difficult to predict. Management will provide further information as and when they are able to.
- AxisBiotix for Acne
The original consumer study with AxisBiotix-Ps? involved participants who had a mix of symptoms from psoriasis, rosacea, and acne. The theory behind the use of a probiotic supplement was to calm and therefore reduce the inflammatory pathways associated with irritable skin conditions. The data showed that as well as alleviating symptoms of psoriasis, the product had an impact on other skin conditions; customer testimonials made reference to its positive effect on eczema, dandruff and acne. As a result of this, management has chosen acne as the next market to address with an adapted form of AxisBiotix?.
During the year, the team has been working on a stabilised bacterial blend from which to choose final formulations for a consumer study in acne. The benefit of undertaking another consumer study is the relatively short time and cost compared to a clinical study and the classification as a food supplement rather than a heavily regulated medical device.
Post year end, in October 2023, SkinBioTherapeutics announced that two separate blends, formulated by Winclove Probiotics BV, had been finalised to be studied side-by-side. A consumer volunteer study is commencing to determine which has better efficacy. The aim is to supply participants with the blends in powder form, just like AxisBiotix-PS?.
The study involves 300 UK-based participants with acne-prone skin, 150 randomly selected participants will receive product 1, the other half of the group will receive product 2. Online recruitment of participants will start via a pre-qualification questionnaire form.
The products will be mailed to participants who are expected to record their experience of using the product in a weekly questionnaire over eight weeks, over which they are expected to take the product daily. A follow-up questionnaire will be provided one month after the participants stop taking their allocated product. The study is expected to be completed and results reported by the end of Q1 2024.
¿MediBiotix? Pilar (aplicaciones de tecnología médica, por ejemplo, cuidado de heridas)
Management is looking at using Skinbiotix? technology in medical device applications, such as woundcare since early data showed that it encourages wound healing. In a similar way to the AxisBiotix-Ps? supplement, management is exploring how SkinBiotix could be developed to alleviate the symptoms of eczema via the gut-skin axis.
The advanced woundcare sector is significant but extremely complex and heavily regulated, therefore, management believes the optimal strategy is to seek a partner with an extensive product portfolio and significant experience in the space to develop this pillar further. Management continues to have advanced conversations with global players in this sector.
CleanBiotix? Pillar (anti-infection)
In early studies of SkinBiotix?, data also suggested that the lysate prevented the most common skin pathogen, Staphylococcus aureus, from sticking to and growing on skin surfaces. Increased use of antibiotics has led to resistance to this infection (MRSA) and incidences are growing more common in hospital settings. Development of SkinBiotix as an anti-infection agent is an exciting opportunity, but, again, management believes it would require taking forward only as part of a wider outlicensed programme with a bigger organisation.
Otros programas de investigación
The Group has continued with its two research programmes with the University of Manchester; an oral programme and an inflammation study.
In August 2022, the first phase of the oral programme was completed and results strongly supported the use of probiotic strains or lysates in the prevention of gum (periodontal) disease. By mixing bacteria and lysates together with oral cells, data suggested that the cells were protected from the pathogens connected with gum disease and reduced inflammation. By changing the type and mix of bacteria to lysate created different levels and elements of protection, therefore, further study is required to optimise the mix. The research and development programme with the University of Manchester continues to uncover novel mechanism by which bacterially derived actives are protective in oral care applications.
Three different actives, and a number of components have been investigated with differentiated activities that offer a route to oral care products with different protective actions on the hard and soft tissues of the oral cavity. This current phase of the programme ends in January 2024 and the company will work with the University to publish relevant findings in H1 2024, and the remainder of the details of the next phase programme through to commercialisation. This lysate is different to that of SkinBiotix.
The inflammation study is still underway. It is looking at how the microbiome can influence and balance the body's response to inflammation specifically related to harmful UVR (sunlight) light. Several first-in-class findings have been made on the effects of bacterially derived components and their ability to regulate the cytokine mediated inflammatory response associated with exposure to UVR. These results strongly support the use of bacterial actives in protecting the skin from sun exposure and a breakout patent filing has been made by the company on a lead active.
The company continues to work with the University of Manchester in further validating these and other findings and in advancing the technology toward human trials. The programme has delivered very encouraging results and has been expanded and extended to allow for the actives identified to be validated in propriety human skin models. The programme will run until June 2025.
Conclusión
In 2023, the majority of the Company's focus has been on growing sales of AxisBiotix-PS? in the UK and starting to push into new European territories, beginning with Spain. Launching a disruptive product into any market always takes time to establish, and given our limited resources, we are pleased with the loyalty and the very positive testimonials we are receiving. The launch into new European markets is very exciting and marks a new chapter.
We continue to enjoy a positive relationship with the Croda/Sederma teams and they have provided very supportive commentary on their views of the SkinBiotix? technology. We see their wish to extend the collaboration for a further 12 months as positive overall; it may delay near-term revenue generation, but the potential enhanced commercial opportunities could be considerable.
Next year should also see the early results from other studies, including the consumer study around an acne product, as well as results from our oral and inflammation programmes with Manchester University. The acne programme is especially exciting. We saw initial positive responses to AxisBiotix-Ps in participants of the psoriasis study who had other skin conditions, and this has resulted in this new development programme which could have a significant impact on a much wider population.
We were very pleased to complete and announce our recent fundraise of £3.3m of gross proceeds in November 2023, which allow the Group to continue to progress its R&D programmes, namely the oral and inflammation programmes.
Talks with potential strategic partners continue around our other pillars. We are also pushing ahead with our inorganic acquisition programme, looking for opportunities that are synergistic and complement our current programmes. We have strict criteria for these opportunities; we will not overpay and they must be accretive from day one.
Martin Hunt (Presidente no ejecutivo)
Stuart J. Ashman (director ejecutivo)
30 November 2023
Estado Consolidado de Renta integral
For the Year Ended 30 June 2023
Notas | 2023 | 2022 | |
Operaciones continuas | £ | £ | |
Ingresos | 3 | 132,057 | 74,761 |
| |||
El costo de ventas |
| (46,867) | (29,424) |
| |||
Beneficio bruto |
| 85,190 | 45,337 |
| |||
Costos de venta y distribución |
| (81,294) | (43,804) |
| |||
Investigación y desarrollo |
| (930,636) | (861,383) |
| |||
Los gastos de explotación |
| (2,072,612) | (2,122,238) |
| |||
Gastos administrativos totales |
| (3,084,542) | (3,027,425) |
| |||
Pérdida de operaciones | 4 | (2,999,352) | (2,982,088) |
| |||
Costos financieros | 5 | (8,886) | (10,135) |
| |||
Pérdida antes de impuestos |
| (3,008,238) | (2,992,223) |
| |||
Taxation |
| 173,089 | 199,622 |
| |||
Pérdida del año | 7 | (2,835,149) | (2,792,601) |
| |||
Otro resultado integral |
| - | - |
Pérdida integral total del año |
| (2,835,149) | (2,792,601) |
Basis and diluted loss per share (pence) | 8 | (1.72) | (1.78) |
Estado financiero consolidado Puesto de trabajo
Al 30 de junio 2023
Notas | 2023 | 2022 | |
Activos |
| £ | £ |
Activos no corrientes |
| ||
Propiedad, planta y equipo. | 10 | 78,658 | - |
Activos por derecho de uso | 11 | 94,502 | 126,903 |
Activos intangibles | 12 | 700,331 | 625,504 |
Total del activo no corriente |
| 873,491 | 752,407 |
| |||
Activos circulantes |
| ||
Los inventarios | 14 | 33,497 | 122,571 |
Cuentas comerciales y otras cuentas por cobrar | 15 | 192,885 | 138,150 |
Impuesto sobre sociedades por cobrar | 15 | 182,545 | 266,916 |
Efectivo y equivalentes de efectivo |
| 1,311,834 | 1,804,923 |
Total de activos corrientes |
| 1,720,761 | 2,332,560 |
los activos totales |
| 2,594,252 | 3,084,967 |
| |||
Patrimonio y pasivos |
| ||
Equidad |
| ||
Capital y reservas |
| ||
Llamado capital social | 19 | 1,731,390 | 1,567,802 |
Compartir premium | 19 | 10,947,874 | 8,758,037 |
Otras reservas |
| 438,589 | 437,316 |
Déficit acumulado |
| (11,122,943) | (8,287,794) |
Equidad total |
| 1,994,910 | 2,475,361 |
| |||
Pasivos |
| ||
Pasivos no corrientes |
| ||
Pasivos por arrendamiento | 17 | 69,601 | 100,647 |
Total pasivo no corriente |
| 69,601 | 100,647 |
| |||
Pasivo circulante |
| ||
Comerciales y otras cuentas a pagar | 16 | 498,696 | 481,742 |
Pasivos por arrendamiento | 17 | 31,045 | 27,217 |
Total pasivo corriente |
| 529,741 | 508,959 |
Pasivos totales |
| 599,342 | 609,606 |
Total patrimonio y pasivos |
| 2,594,252 | 3,084,967 |
|
Estado de Efectivo Consolidado Flujos
For the Year Ended 30 June 2023
2023 | 2022 | |
| £ | £ |
flujos de efectivo por actividades operacionales |
|
|
Pérdida antes de impuestos del período | (3,008,238) | (2,992,223) |
Depreciación de propiedades, planta y equipo | 11,136 | - |
Depreciación e intereses de activos por derecho de uso | 41,287 | 39,557 |
Amortización de IP | 656 | 250 |
Cargo por pagos basados en acciones | 1,273 | 52,704 |
(2,953,886) | (2,889,712) | |
Cambios en el capital de trabajo | ||
Disminución / (aumento) de inventarios | 89,074 | (122,571) |
(lncrease)/decrease in trade and other receivables | (54,735) | 130,796 |
Aumento de cuentas por pagar comerciales y otras | 16,954 | 101,922 |
Efectivo generado por operaciones | 51,293 | 110,147 |
Taxation recibido | 257,458 | 116,534 |
Efectivo neto utilizado en actividades operativas | (2,645,135) | (2,673,031) |
Actividades de inversión | ||
Compra de propiedad, planta y equipo | (89,794) | - |
Compra de PI | (75,483) | (96,813) |
Efectivo neto utilizado en actividades de inversión | (165,277) | (96,813) |
Flujos de efectivo de actividades de financiación | ||
Ingresos netos de la emisión de acciones | 2,353,425 | - |
Pagos de arrendamiento realizados | (36,102) | (35,122) |
Net cash generated by/(used in) financing actividades | 2,317,323 | (35,122) |
Disminución neta de efectivo y efectivo equivalentes | (493,089) | (2,804,966) |
Efectivo y equivalentes de efectivo al comienzo del período | 1,804,923 | 4,609,889 |
Efectivo y equivalentes de efectivo al final del período | 1,311,834 | 1,804,923 |
Estado Consolidado de Cambios en Equidad
For the Year Ended 30 June 2023
Compartir Capital | Compartir premium | Otras reservas | Ganancias retenidas |
Total | |
| £ | £ | £ | £ | £ |
Al 1 de julio de 2021 | 1,567,802 | 8,758,037 | 384,612 | (5,495,193) | 5,215,258 |
Pérdida del período | - | - | - | (2,792,601) | (2,792,601) |
Pagos basados en acciones | - | - | 52,704 | - | 52,704 |
Al 30 de junio de 2022 | 1,567,802 | 8,758,037 | 437,316 | (8,287,794) | 2,475,361 |
Pérdida del período | - | - | - | (2,835,149) | (2,835,149) |
Emisión de acciones | 163,588 | 2,453,793 | - | - | 2,617,381 |
Costo de emisión de acciones | - | (263,956) | - | - | (263,956) |
Pagos basados en acciones | - | - | 1,273 | - | 1,273 |
| |||||
Al 30 de junio de 2023 | 1,731,390 | 10,947,874 | 438,589 | (11,122,943) | 1,994,910 |
|
Estado de situación financiera de la empresa Puesto de trabajo
Al 30 de junio 2023
Notas | 2023 | 2022 | |
Activos |
| £ | £ |
Activos no corrientes |
| ||
Propiedad, planta y equipo. | 10 | 78,658 | - |
Activos por derecho de uso | 11 | 94,502 | 126,903 |
Activos intangibles | 12 | 694,402 | 624,255 |
Inversiones | 13 | 482,434 | 423,072 |
Otros ingresos | 15 | 1,445,801 | 1,142,891 |
Total del activo no corriente |
| 2,795,797 | 2,317,121 |
| |||
Activos circulantes |
| ||
Cuentas comerciales y otras cuentas por cobrar | 15 | 149,157 | 91,427 |
Impuesto sobre sociedades por cobrar | 15 | 182,545 | 230,391 |
Efectivo y equivalentes de efectivo |
| 1,124,961 | 1,561,402 |
Total de activos corrientes |
| 1,456,663 | 1,883,220 |
los activos totales |
| 4,252,460 | 4,200,341 |
| |||
Patrimonio y pasivos |
| ||
Equidad |
| ||
Capital y reservas |
| ||
Llamado capital social | 19 | 1,731,390 | 1,567,802 |
Compartir premium | 19 | 10,947,874 | 8,758,037 |
Otras reservas |
| 438,589 | 437,316 |
Déficit acumulado |
| (9,441,596) | (7,151,781) |
Equidad total |
| 3,676,257 | 3,611,374 |
| |||
Pasivos |
| ||
Pasivos no corrientes |
| ||
Pasivos por arrendamiento | 17 | 69,601 | 100,647 |
Total pasivo no corriente |
| 69,601 | 100,647 |
| |||
Pasivo circulante |
| ||
Comerciales y otras cuentas a pagar | 16 | 475,557 | 461,103 |
Pasivos por arrendamiento | 17 | 31,045 | 27,217 |
Total pasivo corriente |
| 506,602 | 488,320 |
Pasivos totales |
| 576,203 | 588,967 |
Total patrimonio y pasivos |
| 4,252,460 | 4,200,341 |
|
Company Statement of Cash Flujos
For the Year Ended 30 June 2023
2023 | 2022 | |
| £ | £ |
flujos de efectivo por actividades operacionales |
|
|
Pérdida antes de impuestos del período | (2,471,551) | (2,029,989) |
Depreciación de propiedades, planta y equipo | 11,136 | - |
Depreciación e intereses de activos por derecho de uso | 41,287 | 39,557 |
Deterioro de activos financieros | 16,573 | 28,407 |
Cargo por pagos basados en acciones | 1,273 | 52,704 |
(2,401,282) | (1,909,321) | |
Cambios en el capital de trabajo | ||
(lncrease)/decrease in trade and other receivables | (57,731) | (31,539) |
Aumento de cuentas por pagar comerciales y otras | 14,454 | 108,423 |
efectivo (used)/generado por operaciones | (43,277) | 76,884 |
Taxation recibido | 229,583 | 116,534 |
Efectivo neto utilizado en actividades operativas | (2,214,976) | (1,715,903) |
Actividades de inversión | ||
Compra de propiedad, planta y equipo | (89,794) | - |
Compra de PI | (70,147) | (95,314) |
Inversión en subsidiarias | (378,847) | (856,949) |
Efectivo neto utilizado en actividades de inversión | (538,788) | (952,263) |
Flujos de efectivo de actividades de financiación | ||
Ingresos netos de la emisión de acciones | 2,353,425 | - |
Pagos de arrendamiento realizados | (36,102) | (35,122) |
Net cash generated by/(used in) financing actividades | 2,317,323 | (35,122) |
Disminución neta de efectivo y efectivo equivalentes | (436,441) | (2,703,288) |
Efectivo y equivalentes de efectivo al comienzo del período | 1,561,402 | 4,264,690 |
Efectivo y equivalentes de efectivo al final del período | 1,124,961 | 1,561,402 |
Estado de cambios de la empresa en Equidad
For the Year Ended 30 June 2023
Compartir Capital | Compartir premium | Otras reservas | Ganancias retenidas |
Total | |
| £ | £ | £ | £ | £ |
Al 1 de julio de 2021 | 1,567,802 | 8,758,037 | 384,612 | (5,284,889) | 5,425,562 |
Pérdida del período | - | - | - | (1,866,892) | (1,866,892) |
Pagos basados en acciones | - | - | 52,704 | - | 52,704 |
Al 30 de junio de 2022 | 1,567,802 | 8,758,037 | 437,316 | (7,151,781) | 3,611,374 |
Pérdida del período | - | - | - | (2,289,815) | (2,289,815) |
Emisión de acciones | 163,588 | 2,453,793 | - | - | 2,617,381 |
Costo de emisión de acciones | - | (263,956) | - | - | (263,956) |
Pagos basados en acciones | - | - | 1,273 | - | 1,273 |
| |||||
Al 30 de junio de 2023 | 1,731,390 | 10,947,874 | 438,589 | (9,441,596) | 3,676,257 |
Notas a la Financiera Declaraciones
For the Year Ended 30 June 2023
1. Información General
SkinBioTherapeutics plc ('the Company') is a public limited company incorporated in England under the Companies Act and quoted on the AIM market of the London Stock Exchange (AIM: SBTX).
La principal actividad del Grupo es la identificación y desarrollo de tecnología que aproveche el microbioma humano para mejorar la salud.
2. Significant accounting policies and basis of preparation
a) Declaración de cumplimiento
The consolidated and company financial statements of SkinBioTherapeutics plc have been prepared in accordance with UK-adopted International Accounting Standards ('IFRS') and the Companies Act 2006 applicable to companies reporting under IFRS.
b) Base de preparación
The consolidated and company financial statements have been prepared under the historical cost convention modified by the revaluation of certain financial instruments. The accounting policies have been applied consistently in all material respects.
The consolidated and company financial statements are presented in Sterling (£) as this is the predominant functional currency of the Group and Company, and is the currency of the primary economic environment in which it operates. Foreign transactions are accounted in accordance with the policies set out below.
c) Base de consolidación
The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company (its subsidiaries) made up to 30 June each year. Control is achieved where the Company has the power to govern the financial and operating policies of an investee entity so as to obtain benefits from its activities. All intra-group transactions, balances, income and expenses are eliminated on consolidación.
d) Preocupación continua
These financial statements have been prepared on a going concern basis. In considering the appropriateness of this assumption, the Board has considered the Group's projections for the twelve months from the date of approval of this financial information, including cash flow forecasts. The directors are confident that based on the Group's forecasts and the recently completed capital raise of approximately £3.3 million (before costs) the Group will have enough funds to continue in operation for at least 12 months from the date of signing these financial statements. The Directors believe that the Group has adequate resources to continue in operational existence for the foreseeable future and therefore adopt the going concern basis of accounting in preparing these financial statements.
e) Estimaciones y juicios
The preparation of financial statements requires the Board to make judgements, estimates and assumptions that may affect the application of accounting policies and reported amounts of assets and liabilities as at each balance sheet date and the reported amounts of revenues and expenses during each reporting period. Any estimates and assumptions are based on experience and any other factors that are believed to be relevant under the circumstances and which the Board considers to be reasonable. Actual outcomes may differ from these estimates. Any revisions to accounting estimates will be recognised in the period in which the estimate is revised if the revision affects only that period. If the revision affects both current and future periods, the change will be recognised over those periods.
The following are the critical judgements that the Directors have made in the process of applying the Group's accounting policies and that have the most significant effect on the amounts recognised in the consolidated financial statements.
Estimation of the lifetime of intangible activos
Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortization and accumulated impairment losses.
Intangible assets recognised are reviewed against the criteria for capitalisation with useful life determined by reference to the underlying product being developed. Management believes that the assigned values and useful lives, as well as the underlying assumptions, are reasonable, though different assumptions and assigned lives could have a significant impact on the reported amounts.
Useful lives are also examined on an annual basis and adjustments, where applicable are made on a prospective basis. The Group does not have any intangible assets with indefinite lives.
Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:
Intellectual property - 20% straight line
Capitalización de costos de desarrollo
During the year £75,483 (2022: £96,813) of development costs were capitalised, bringing the total amount of development costs capitalised, as intangible assets, as at 30 June 2023, to £700,331 (2022: £625,504), net of amortisation. Management has reviewed the balances by project, compared the carrying amount to expected future revenues and is satisfied that no impairment exists and that the costs capitalised will be fully recovered as the products are launched to market. New product projects are monitored regularly and should the technical or market feasibility of a new product be in question, the project would be cancelled and capitalised costs to date will be removed from the balance sheet and charged to the statement of comprehensive income.
Valoración de inventario
Inventory is carried at the lower of cost and net realisable value, using the first in first out method. Appropriate provisions for estimated irrecoverable amounts due to slow-moving or obsolete inventory are recognised in the income statement where there is objective evidence that the assets are impaired.
The provision is £35,386 at 30 June 2023 (2022: £265,966).
Refund accruals
Accruals for sales returns are estimated on the basis of historical returns and are recorded so as to allocate them to the same period in which the original revenue is recorded. These accruals are reviewed regularly and updated to reflect The Boards's latest best estimates. The Board do not believe that the difference between the accrual estimate and actual returns will be material.
The accrual for net refunds totalled £82 at 30 June 2023 (2022: £267). The expected returns rate would need to differ to actual returns by 10% to have an impact of +/- £1,014 on reported revenue and on operating profit. The choice of a 10% change for the determination of sensitivity represents an extreme variation in the return rate.
Pagos basados en acciones
The Group measures the cost of equity-settled transactions with employees by reference to the fair value of the equity instruments at the date at which they are granted. The fair value is determined by using the Black-Scholes model taking into account the terms and conditions upon which the instruments were granted. The accounting estimates and assumptions relating to equity-settled share-based payments would have no impact on the carrying amounts of assets and liabilities within the next annual reporting period but may impact profit or loss and equity. The judgments made and the model used are further specified in note 20.
Estimation of incremental borrowing rate in accounting for leases under IFRS16 - TecXNUMXCloud
In recognising a lease liability and right-of-use asset under IFRS 16 the Group has used an estimated incremental borrowing rate of 8%. The Group does not have any borrowings, so in order to apply IFRS 16 it was necessary to estimate the incremental borrowing rate that would be faced by the Group. The rate of 8% was determined by looking at a range of loans available on the market. If the interest rate used in the calculation were higher, this would have the effect of reducing the size of both the lease liability and right-of-use asset, reducing the depreciation charge and increasing the interest charge in the consolidated income statement. The overall change to the Company Income Statement and the Company Statement of Financial Position would be immaterial. There would be no change to operating cash flows or lease payments as a result of a change in the estimate of the incremental interest rate.
f) Application of new and re vised International Financial Reporting Standards (IFRSs)
The Group has adopted all of the new or amended Accounting Standards and interpretations issued by the International Accounting Standards Board ('IASB') or the IFRS Interpretations Committee ('IFRIC') that are mandatory and relevant to The Group's activities for the current reporting period.
No new standards or interpretations issued by the IASB or the IFRIC have led to any material changes in the Group's accounting policies or disclosures during each reporting period.
NIIF nuevas y revisadas en circulación pero aún no eficaz
There are a number of new and revised IFRSs that have been issued but are not yet effective that the Group has decided not to adopt early. The most significant of these are as follows:
Referencia | Título | Resumen | Fecha de aplicación de la norma (Períodos que comienzan en o después) |
IFRS17 - TecXNUMXCloud | Contratos de seguros | Principles for the recognition, measurement, presentation and disclosure of insurance contratos
Modificaciones para abordar las preocupaciones y los desafíos de implementación que se identificaron después de la publicación de la NIIF 17
| 1 de enero de 2023
1 de enero de 2023 |
IAS1 | Presentación de estados financieros | Amendments regarding the classification of liabilities as current or non-current
| 1 de enero de 2023 |
IAS8 | Accounting Policies, Changes in Accounting Estimates | Modificaciones a la definición de estimaciones contables
| 1 de enero de 2023 |
IAS12 | Impuestos sobre la renta | Impuesto diferido relacionado con activos y pasivos que surgen de una sola transacción
| 1 de enero de 2023 |
IAS37 | Amendments to IAS1 and IFRS Practice Statement 2 | Amendments regarding disclosure of material accounting policies
| 1 de enero de 2023 |
The adoption of these Standards and Interpretations is not expected to have a material impact on the financial information of the Group in the period of initial application when they come into effect.
3. Información segmentaria
IFRS 8 'Operating Segments' requires operating segments to be determined based on The Group's internal reporting to the Chief Operating Decision Maker. The Chief Operating Decision Maker has been determined to be The Board of Directors which receives information on the basis of the Group's operations in key geographical territories, based on the Group's management and internal reporting structure. Based on this assessment the Group consider there to be 3 operating segments. Despite there being 3 operating segments, it is not currently feasible to allocate assets and liabilities to the operating segments. As these operating segments grow, we expect that allocation of assets and liabilities will be possible. Administrative expenses are not segmented for accounting purposes as the Board do not review these by segment currently.
| Año terminado el 30 de junio de 2023 | |||||||
| UK |
| US |
| EU |
| Total | |
| £ |
| £ |
| £ |
| £ | |
Las ventas minoristas | 118,921 | 9,275 | 3,861 | 132,057 | ||||
El costo de ventas | (42,205) | (3,292) | (1,370) | (46,867) | ||||
Beneficio bruto | 76,716 | 5,983 | 2,491 | 85,190 |
| Año terminado el 30 de junio de 2022 | |||||||
| UK |
| US |
| EU |
| Total | |
| £ |
| £ |
| £ |
| £ | |
Las ventas minoristas | 57,687 | 17,074 | - | 74,761 | ||||
El costo de ventas | (23,264) | (6,160) | - | (29,424) | ||||
Beneficio bruto | 34,423 | 10,914 | - | 45,337 |
Debido a la naturaleza de sus actividades, el Grupo no depende de ningún cliente importante individual.
4. Expenses - analysis by nature
|
| Grupo procesos | Grupo procesos |
|
| 2023 | 2022 |
|
| £ | £ |
Otros ingresos |
| (3,292) | (1,032) |
Costos de venta y distribución |
| 81,294 | 43,804 |
Depreciación del activo por derecho de uso |
| 32,401 | 29,422 |
Depreciación de planta y equipo |
| 11,136 | - |
Investigación y desarrollo |
| 930,636 | 861,383 |
Directors remuneration (including share-based compensation) |
| 778,639 | 624,564 |
Gastos de personal |
| 214,606 | 142,342 |
Diferencias de cambio de divisas |
| (51) | 1,127 |
La remuneración del Auditor |
| ||
- honorarios de auditoría |
| 34,450 | 26,250 |
- otros servicios |
| 3,000 | 2,260 |
Anotar inventario |
| 35,386 | 265,966 |
Otros costos operativos |
| 966,337 | 1,031,339 |
Gastos totales de operación |
| 3,084,542 | 3,027,425 |
5. Costos financieros
|
|
|
|
|
| Grupo procesos | Grupo procesos |
|
| 2023 | 2022 |
|
| £ | £ |
Intereses por pagar |
| 8,886 | 10,135 |
| 8,886 | 10,135 |
Interest payable represents amounts arising on leases accounted for under IFRS 16.
6. Employees and Directors
|
|
| ||
Grupo y empresa |
| 2023 | 2022 | |
The average monthly number of employees and senior management was: |
| Número | Número | |
Directores ejecutivos |
| 2 | 2 | |
Directores no ejecutivos |
| 3 | 2 | |
Empleados |
| 7 | 4 | |
Promedio total de personas ocupadas |
| 12 | 8 | |
As at 30 June 2023 the Company had 11 employees (2022: 7).
|
|
| ||
Grupo y empresa |
| 2023 | 2022 | |
Staff costs in respect of these employees were: |
| £ | £ | |
Sueldos y salarios |
| 1,012,909 | 631,789 | |
Costos de seguridad social |
| 137,531 | 68,816 | |
Defined contribution pensions |
| 19,733 | 16,883 | |
Pagos basados en acciones (ver nota 20) |
| 1,273 | 52,704 | |
Remuneración total |
| 1,171,446 | 770,192 | |
| ||||
All staff were directly employed by SkinBioTherapeutics Sociedad Anónima.
Some of these staff costs are included within research and development and some in share issue costos.
All the directors above can be considered to be key management and have the responsibility for planning, directing and controlling, directly or indirectly, the activities of the Company.
The remuneration of directors and key executives is determined by the remuneration committee having regard to the performance of individuals and market trends.
The Company operates a defined contribution pension scheme for employees and directors. The assets of the scheme are held separately from those of the Company in independently administered funds. The amounts outstanding at 30 June 2023 are £3,326 (2022: £2,633).
Grupo y empresa |
| 2023 | 2022 |
Directors remuneration: |
| £ | £ |
Stuart J. Ashman |
| 382,478 | 368,449 |
Manprit Randhawa |
| 261,480 | 14,951 |
doug quinn |
| - | 140,414 |
martin caza |
| 68,670 | 63,000 |
Dr Cathy Prescott |
| 41,011 | 31,500 |
Danielle Bekker |
| 25,000 | 6,250 |
Remuneración total |
| 778,639 | 624,564 |
|
|
| |
Que se compone de: |
|
|
|
|
|
| |
Remuneración |
| 755,258 | 572,151 |
Amounts receivable under long term incentive schemes |
| 11,375 | 42,603 |
Aportaciones de la empresa a planes de pensiones |
| 12,006 | 9,810 |
Remuneración total |
| 778,639 | 624,564 |
|
|
|
The number of directors to whom retirement benefits are accruing in respect of qualifying services under defined contribution pension schemes is 2 (2022: 2). The highest paid director received total emoluments of £382,478 (2022: £368,449) during the year.
7. Fiscalidad
Impuestos a las ganancias reconocidos en utilidad o pérdida |
| 2023 | 2022 |
|
| £ | £ |
Impuesto corriente |
|
|
|
Período actual: impuesto de sociedades del Reino Unido |
| - | - |
Crédito fiscal por I + D |
| 182,547 | 173,729 |
Crédito fiscal por I + D - año anterior |
| (8,458) | 25,893 |
Crédito fiscal del año |
| 173,089 | 199,622 |
The tax charge for each period can be reconciled to the loss per the statement of comprehensive income as manera:
Pérdidas imponibles |
| (3,008,238) | (2,992,223) |
Normal applicable rate of tax |
| 19.00% | 19.00% |
Loss on ordinary activities multiplied by normal rate of tax |
| (571,565) | (568,522) |
| |||
Efectos de: |
| ||
Depreciación | 2,116 | - | |
No permitidos | 3,752 | 12,525 | |
Permisos de capital | (17,061) | - | |
Deducciones mejoradas en I + D | (137,215) | (128,668) | |
Crédito fiscal por I + D | (173,089) | (199,622) | |
Losses surrendered | 248,189 | 227,644 | |
Pérdidas fiscales no utilizadas arrastradas | 471,784 | 457,021 | |
UK tax charge/(credit) |
| (173,089) | (199,622) |
The Group has an unrecognised deferred tax asset of £1,637,470 (2022: £1,132,844) at the period end, which has not been recognised in the financial statements due to uncertainty of future profits. The Group has an estimated tax loss of £8,618,261 (2022: £5,962,339) available to be carried forward against future profits.
8. Pérdida por acción
| 2023 | 2022 | |
|
| £ | £ |
Pérdida por acción básica y diluida |
|
|
|
Pérdida integral total del año |
| (2,835,149) | (2,792,601) |
Número medio ponderado de acciones |
| 164,713,045 | 156,780,236 |
Pérdida básica y diluida por acción (peniques) |
| (1.72) | (1.78) |
As the Group and Company are reporting a loss from continuing operations for the year then, in accordance with IAS 33, the share options are not considered dilutive because the exercise of the share options would have an anti-dilutive effect. The basic and diluted earnings per share as presented on the face of the income statement are therefore identical.
9. Company's result for the period
The Group has elected to take the exemption under section 408 of the Companies Act 2006 not to present the Parent Company income statement account.
The loss for the Parent Company for the period was £2,289,815 (2022: £ 1,866,892).
10. Propiedades, planta y equipo
Grupo y empresa
| Planta y Maquinaria | |
| £ | |
Cost | ||
Al 1 de julio de 2021 | 10,200 | |
Adiciones | - | |
Al 30 de junio de 2022 | 10,200 | |
Adiciones | 89,794 | |
Al 30 de junio de 2023 |
| 99,994 |
Depreciación acumulada | ||
Al 1 de julio de 2021 | 10,200 | |
Cobrar por el año | - | |
Al 30 de junio de 2022 | 10,200 | |
Cobrar por el año | 11,136 | |
Al 30 de junio de 2023 |
| 21,336 |
Valor neto contable | ||
Al 1 de julio de 2021 | - | |
Al 30 de junio de 2022 | - | |
Al 30 de junio de 2023 |
| 78,658 |
11. Activos por derecho de uso
Grupo y empresa |
|
|
|
| |
|
| Total | |||
|
| £ | |||
Cost | |||||
Al 1 de julio de 2021 | 145,757 | ||||
Adiciones | 12,997 | ||||
Al 30 de junio de 2022 | 158,754 | ||||
Al 30 de junio de 2023 |
|
| 158,754 | ||
Amortización acumulada | |||||
Al 1 de julio de 2021 | 2,429 | ||||
Cobrar por el año | 29,422 | ||||
Al 30 de junio de 2022 | 31,851 | ||||
Cobrar por el año | 32,401 | ||||
Al 30 de junio de 2023 |
|
| 64,252 | ||
Valor neto contable | |||||
Al 1 de julio de 2021 | 143,328 | ||||
Al 30 de junio de 2022 | 126,903 | ||||
Al 30 de junio de 2023 |
|
| 94,502 | ||
12. Activos intangibles
| Patents & trademarks | Patents & trademarks | |
| Grupo procesos | Empresa | |
| £ | £ | |
Cost | |||
Al 1 de julio de 2021 | 528,941 | 528,941 | |
Adiciones | 96,813 | 95,314 | |
Al 30 de junio de 2022 | 625,754 | 624,255 | |
Adiciones | 75,483 | 70,147 | |
Al 30 de junio de 2023 |
| 701,237 | 694,402 |
Amortización acumulada | |||
Al 1 de julio de 2021 | - | - | |
Cobrar por el año | 250 | - | |
Al 30 de junio de 2022 | 250 | - | |
Cobrar por el año | 656 | - | |
Al 30 de junio de 2023 |
| 906 | - |
Valor neto contable | |||
Al 1 de julio de 2021 | 528,941 | 528,941 | |
Al 30 de junio de 2022 | 625,504 | 624,255 | |
Al 30 de junio de 2023 |
| 700,331 | 694,402 |
Intellectual property is to be amortised over the expected period that the asset generates income. A small part of the IP belonging to the active subsidiary, AxisBiotix Limited, commenced amortisation in the year ending 30 June 2022. Other IP amortisation is expected to commence in the year ending 30 June 2024.
13. Inversiones
Company: Investments in subsidiary undertakings |
| £ |
|
|
|
Cost |
|
|
Al 1 de julio de 2021 |
| 113,733 |
Adiciones |
| 309,339 |
Al 30 de junio de 2022 |
| 423,072 |
Adiciones |
| 59,362 |
Al 30 de junio de 2023 |
| 482,434 |
As at 30 June 2023, the Company directly owned the following subsidiarias:
Nombre de la compañía | País de constitución | Proportion of equity interest |
SkinBiotix Limited | Reino Unido | 100% de acciones ordinarias |
AxisBiotix Limited | Reino Unido | 100% de acciones ordinarias |
MediBiotix Limited | Reino Unido | 100% de acciones ordinarias |
CleanBiotix Limited | Reino Unido | 100% de acciones ordinarias |
PharmaBiotix Limited | Reino Unido | 100% de acciones ordinarias |
14. Inventarios
|
| 2023 | 2022 |
|
| £ | £ |
Los inventarios |
| 33,497 | 122,571 |
| 33,497 | 122,571 |
The cost of inventories recognised as an expense during the year was £82,252 (2022: £295,390).
The cost of inventories recognised as an expense includes £35,386 (2022: £265,966) in respect of write-downs of inventory to net realisable value.
15. Cuentas por cobrar comerciales y otras
| ||||
2023 | 2022 | 2023 | 2022 | |
£ | £ | £ | £ | |
Current | ||||
Deudores comerciales | 816 | 1,800 | - | - |
impuesto de sociedades | 182,545 | 266,916 | 182,545 | 230,391 |
Sales taxes recoverable | 108,720 | 48,669 | 96,240 | 13,560 |
Otros ingresos | 12,693 | 11,101 | 12,891 | 11,101 |
Prepagos | 70,656 | 76,580 | 40,026 | 66,766 |
| 375,430 | 405,066 | 331,702 | 321,818 |
No corriente | ||||
Importes adeudados por empresas del grupo | - | - | 1,445,801 | 1,142,891 |
- | - | 1,445,801 | 1,142,891 |
The fair values of the Company's current trade and other receivables are considered to equate to their carrying amounts. The maximum exposure to credit risk for trade receivables is represented by their carrying amount. There are no financial assets which are past due but not impaired. No current financial assets are impaired.
The amounts owed by subsidiary undertakings include a loan to AxisBiotix Limited for £1,788,549 (2022:£1,531,177) which was discounted to £1,524,909 and then impaired by £16,573, in addition to earlier years impairment of £62,531 to give a current value of £1,445,801 (2022: £1,142,891) under IFRS 9, as set out in note 2. Although the loan has no repayment terms, it is anticipated to be repaid in 3 years from the date of these financial statements.
16. Acreedores comerciales y otras cuentas por pagar
| ||||
2023 | 2022 | 2023 | 2022 | |
£ | £ | £ | £ | |
Current | ||||
Acreedores comerciales | 194,274 | 72,610 | 176,176 | 66,277 |
Acumulaciones | 236,837 | 366,784 | 233,839 | 353,534 |
Sales taxes payable | 505 | 85 | - | - |
Otros impuestos | 62,815 | 31,812 | 61,636 | 31,059 |
Otras cuentas por pagar | 4,265 | 10,451 | 3,906 | 10,233 |
| 498,696 | 481,742 | 475,557 | 461,103 |
Trade and other payables principally consist of amounts outstanding for trade purchases and ongoing costs. They are non-interest bearing and are normally settled on 30-day terms. The directors consider that the carrying value of trade and other payables approximates to their fair value. All trade and other payables are denominated in Sterling. The Company has financial risk management policies in place to ensure that all payables are paid within the credit timeframe and no interest has been charged by any suppliers as a result of late payment of invoices during the period.
The fair value of trade and other payables approximates their current book valores.
17. Pasivos por arrendamiento
Grupo y empresa
| 2023 | 2022 | |
| £ | £ | |
Análisis de madurez | |||
Primer ano | 37,770 | 36,102 | |
Primer ano | 39,029 | 37,770 | |
Primer ano | 35,777 | 39,029 | |
Primer ano | - | 35,778 | |
Primer ano | - | - | |
112,576 | 148,679 | ||
Less future interest charges | (11,930) | (20,815) | |
|
| 100,646 | 127,864 |
Analizado como | |||
Current | 31,045 | 27,217 | |
No corriente | 69,601 | 100,647 | |
|
| 100,646 | 127,864 |
18. Instrumentos financieros
Madurez análisis
A summary table with maturity of financial assets and liabilities presented below is used by management to manage liquidity risks. The amounts disclosed in the following tables are the contractual undiscounted cash flows. Undiscounted cash flows in respect of balances due within 12 months generally equal their carrying amounts in the statement of financial position, as the impact of discounting is not material.
The maturity analysis of financial instruments at 30 June 2023 is as manera:
Grupo procesos |
|
|
|
|
| |
Importe en libros | On demand and less than 3 months | 3 al mes 12 | 1 a 2 años | 2 a 5 años | ||
Activos | ||||||
Efectivo y equivalentes de efectivo | 1,311,834 | 1,311,834 | - | - | - | |
Cuentas comerciales y otras cuentas por cobrar | 13,509 | 13,509 | - | - | - | |
1,325,343 | 1,325,343 | - | - | - | ||
Pasivos | ||||||
Comerciales y otras cuentas a pagar | 435,881 | 435,881 | - | - | - | |
Pasivos por arrendamiento | 112,576 | 8,498 | 29,272 | 39,029 | 35,777 | |
548,457 | 444,379 | 29,272 | 39,029 | 35,777 |
Empresa |
|
|
|
|
| |
Importe en libros | On demand and less than 3 months | 3 al mes 12 | 1 a 2 años | 2 a 5 años | ||
Activos | ||||||
Efectivo y equivalentes de efectivo | 1,124,961 | 1,124,961 | - | - | - | |
Cuentas comerciales y otras cuentas por cobrar | 12,892 | 12,892 | - | - | - | |
1,137,853 | 1,137,853 | - | - | - | ||
Pasivos | ||||||
Comerciales y otras cuentas a pagar | 413,923 | 413,923 | - | - | - | |
Pasivos por arrendamiento | 112,576 | 8,498 | 29,272 | 39,029 | 35,777 | |
526,499 | 422,421 | 29,272 | 39,029 | 35,777 |
The maturity analysis of financial instruments at 30 June 2022 is as manera:
Grupo procesos |
|
|
|
|
| |
Importe en libros | On demand and less than 3 months | 3 al mes 12 | 1 a 2 años | 2 a 5 años | ||
Activos | ||||||
Efectivo y equivalentes de efectivo | 1,804,923 | 1,804,923 | - | - | - | |
Cuentas comerciales y otras cuentas por cobrar | 12,901 | 12,901 | - | - | - | |
1,817,824 | 1,817,824 | - | - | - | ||
Pasivos | ||||||
Comerciales y otras cuentas a pagar | 449,930 | 449,930 | - | - | - | |
Pasivos por arrendamiento | 133,501 | 5,854 | 26,341 | 33,989 | 67,317 | |
583,431 | 455,784 | 26,341 | 33,989 | 67,317 |
Empresa |
|
|
|
|
| |
Importe en libros | On demand and less than 3 months | 3 al mes 12 | 1 a 2 años | 2 a 5 años | ||
Activos | ||||||
Efectivo y equivalentes de efectivo | 1,561,402 | 1561,402 | - | - | - | |
Cuentas comerciales y otras cuentas por cobrar | 1,542,278 | 11,101 | - | - | 1,531,177 | |
3,103,680 | 1,572,503 | - | - | 1,531,177 | ||
Pasivos | ||||||
Comerciales y otras cuentas a pagar | 430,044 | 430,044 | - | - | - | |
Pasivos por arrendamiento | 133,501 | 5,584 | 26,341 | 33,989 | 67,317 | |
563,545 | 435,898 | 26,341 | 33,989 | 67,317 |
18. Capital social
| Numero de veces compartido | Compartir capital | Compartir producto de más alta calidad. | |
Al 1 de julio de 2021 | 156,780,236 | 1,567,802 | 8,758,037 | |
Al 30 de junio de 2022 | 156,780,236 | 1,567,802 | 8,758,037 | |
Ordinary share issued at 1p per share | 16,358,618 | 163,588 | 2,453,793 | |
Costos relacionados con las acciones emitidas | - | - | (263,956) | |
Al 30 de junio de 2023 |
| 173,138,854 | 1,731,390 | 10,947,874 |
On 5 January 2023 16,358,618 ordinary shares were issued by way of a placing at a price of 16p per share to raise funding for the Group.
Share capital is the amount subscribed for shares at nominal value, issued and fully pagado.
Share premium is the amount subscribed for share capital in excess of nominal .
19. Pagos basados en acciones
Compartir opciones
The Group operates share-based payment arrangements to remunerate directors and others providing similar services in the form of a share option scheme. The exercise price of the option is normally equal to the market price of an ordinary share in the Group at the date of grant. Each share option converts into one ordinary share of the Group on exercise. No amounts are paid or payable by the recipient on receipt of the option. The options carry neither rights to dividends nor voting rights.
Los movimientos en el número de opciones sobre acciones en circulación y sus correspondientes precios de ejercicio promedio ponderados son los siguientes:
Grupo y empresa |
|
| |||
| 2023 |
| 2022 |
| |
| Number of options | Precio de ejercicio promedio ponderado | Number of options | Precio de ejercicio promedio ponderado | |
£ |
| £ | |||
Sobresaliente al 1 de julio | 17,379,343 | 0.12 | 16,729,343 | 0.11 | |
Otorgado durante el año | - | - | 650,000 | 0.38 | |
Perdido / cancelado durante el año | (650,000) | 0.38 | - | - | |
Sobresaliente al 30 de junio | 16,729,343 | 0.11 | 17,379,343 | 0.12 |
On 9 May 2023, 650,000 options were forfeited, which were previously granted at an exercise price of £0.376 per share.
The total credit recognised for the year ended 30 June 2023 for these share options is -£10,102, whereas in 2022 this was a charge of £10,102.
The fair values of the share options issued in the year were derived using the Black Scholes model. The charge recognised for the year ended 30 June 2023 for share options is £11,375 (2022: £52,704) amounting to a total net charge of £1,273 being recognised in the profit and loss account. The following assumptions were used in the calculations:
|
|
|
|
|
| |
Deed pool | 1 | 2 | 3a | 3b | 3c | |
Fecha de concesión | 05/04/17 | 05/04/17 | 05/04/17 | 05/04/17 | 05/04/17 | |
Precio de ejercicio | 9p | 9p | 9p | 9p | 9p | |
Precio de la acción en la fecha de concesión | 9p | 9p | 9p | 9p | 9p | |
Tasa libre de riesgo | 0.24% | 0.24% | 0.16% | 0.16% | 0.16% | |
Volatilidad | 60% | 60% | 60% | 60% | 60% | |
Vida esperada | 3.5 años | 3.5 años | 2.75 años | 2.75 años | 2.75 años | |
Valor razonable | 2.58p | 1.85p | 2.30p | 2.30p | 2.30p |
|
|
|
|
|
| |
Deed pool | 4 | 5 | 6 | 7 | 8 | |
Fecha de concesión | 18/04/19 | 18/04/19 | 18/04/19 | 03/03/20 | 08/04/20 | |
Precio de ejercicio | 18p | 18p | 18p | 9.5p | 9p | |
Precio de la acción en la fecha de concesión | 18p | 18p | 18p | 9.5p | 7p | |
Tasa libre de riesgo | 0.75% | 0.75% | 0.75% | 0.29% | 0.12% | |
Volatilidad | 60% | 60% | 60% | 80% | 80% | |
Vida esperada | 3.5 años | 3.5 años | 3.5 años | 0 años | 2 años | |
Valor razonable | 2.85p | 3.99p | 3.48p | 9.50p | 0.87p |
The closing share price per share at 30 June 2023 was 12.5p (30 June 2022: 20.25p).
Expected volatility is based on a conservative estimate for an AIM listed entity. The expected life used in the model has been adjusted, based on management's best estimate, for the effects of non-transferability, exercise restrictions and behavioural considerations.
20. Transacciones con partes relacionadas
Grupo y empresa |
|
|
|
Compensación del personal de gestión clave |
| 2023 | 2022 |
|
| £ | £ |
Short-term employee benefits including social security costs | 934,467 | 694,844 | |
Beneficios post-empleo | 13,218 | 11,239 | |
Pagos basados en acciones | 11,375 | 42,603 | |
959,060 | 748,686 |
Compensation figures above include directors and key management personnel.
Transacciones con otras partes relacionadas
During the period ended 30 June 2023, the Company was charged fees of £55,440 (2022: £50,400) by Invictus Management Ltd, a company in which Martin Hunt, a director of the Company, is also a director. These fees relate to Martin Hunt's consultancy services to the Company. As at 30 June 2023 £5,292 (2022: £5,040) was sobresaliente.
During the period ended 30 June 2023, the Company was charged fees of £28,096 (2022: £25,200) by Biolatris Ltd, a company in which Dr Cathy Prescott, a director of the Company, is also a director. These fees relate to Dr Cathy Prescott's consultancy services to the Company. As at 30 June 2023 £nil (2022: £nil) was outstanding.
21. Partido controlador supremo
No one shareholder has control of the Compañía.
22. Hechos posteriores a la fecha de presentación
La Sociedad ha evaluado todos los hechos y transacciones ocurridos con posterioridad al 30 de junio de 2023 hasta la fecha de firma de los estados financieros.
On 22 November 2023 the Company completed a fundraise through a Placing and Retail Offer, raising £3.3m of gross proceeds.
No otros material subsequent events have occurred that would require adjustment to or disclosure in the financial Declaraciones.
RNS puede usar su dirección IP para confirmar el cumplimiento de los términos y condiciones, para analizar cómo interactúa con la información contenida en esta comunicación y para compartir dicho análisis de forma anónima con otros como parte de nuestros servicios comerciales. Para obtener más información sobre cómo RNS y la Bolsa de Valores de Londres utilizan los datos personales que nos proporciona, consulte nuestra Política de privacidad.